Kaposi's sarcoma with visceral involvement after intraarticular and epidural injections of corticosteroids

Trattner, Akiva; Hodak, Emmilia; David, Michael; Neeman, A; Sandbank, Miriam

doi:10.1016/0190-9622(93)70264-t

Cited by 24 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been recognized that glucocorticoids have a major role in KS development, [9-11] and their withdrawal may induce regression of KS lesions [12,13]. In vitro they have a synergistic effect with oncostatin, an autocrine element involved in KS-cells proliferation.…”

Section: Resultsmentioning

confidence: 99%

Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not"

2007

View full text Add to dashboard Cite

Background: Imatinib is a tyrosine-kinase inhibitor; for which there is limited information regarding its effects on AIDS Kaposi's sarcoma and none in patients with transplant-associated Kaposi's sarcoma. Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor), clinical benefit has been reported in Kaposi's sarcoma associated with renal graft.

show abstract

Section: Resultsmentioning

confidence: 99%

Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not"

2007

View full text Add to dashboard Cite

show abstract

“…KS was reported to develop after standard glucocorticosteroid therapy alone for a wide variety of inflammatory diseases in various doses and treatment periods [5,15,16,17,18,19,20,21]. In most of the reported cases, spontaneous regression occurred after treatment discontinuation.…”

Section: Discussion and Reviewmentioning

confidence: 99%

“…In most of the reported cases, spontaneous regression occurred after treatment discontinuation. When specified, the time to achieve clinical remission ranged from 4 to 7 months [15,22,23]. …”

Section: Discussion and Reviewmentioning

confidence: 99%

Kaposi’s Sarcoma after Long-Acting Steroids: Time until Remission and Drug Washout

et al. 2010

View full text Add to dashboard Cite

Long-acting steroids (LAS) are widely used to treat various inflammatory diseases and allergies. They have many adverse effects including the inhibition of the hypothalamopituitary axis that can last several months. LAS are also strong immunosuppressors and can result in severe opportunistic infections and immunodeficiency-related malignancies. However, the time needed for immune recovery after withdrawal of LAS is unknown. Here we report a case of Kaposi’s sarcoma (KS) and severe immunosuppression after a chronic triamcinolone acetonide (TA) treatment. Six months after withdrawal, traces of TA were still detected in the serum by HPLC mass spectrometry. At 8 months, the drug became undetectable, and clinical and biological signs of immune recovery – beginning of KS regression, normalization of IgG levels and CD4 T lymphocyte counts – became noticeable. We then provide a review of the literature on the time until remission of KS after immunosuppression reduction. We also reviewed the cases of KS induced by TA, and the metabolic side effects of TA when compared to standard glucocorticoids.

show abstract

“…The development of Kaposi's sarcoma after treatment with corticosteroids has been reported in only 38 patients who have not had acquired immunodeficiency syndrome or undergone organ transplantation [1]. Data from the literature clearly show that corticosteroid therapy may trigger the development of Kaposi's sarcoma in patients who usually possess several other pathogenetic factors of that disease, such as pre-existing immune deficiency, environmental (viruses) or genetic factors [2].…”

Section: Discussionmentioning

confidence: 99%

Kaposi's sarcoma complicating long-term corticotherapy for rheumatoid arthritis

Elloudi¹,

Elmahi²,

Gallouj³

et al. 2017

Our Dermatol Online

View full text Add to dashboard Cite

Kaposi's sarcoma (KS) is a lymphoangioproliferative neoplasm induced by human herpes virus 8 (HHV-8). KS caused by iatrogenic immunosuppression is rare. Iatrogenic KS can present a therapeutic dilemma, as decreasing the level of immunosuppression may not be possible or may come at the high cost of organ rejection, such as in the case of organ transplant recipients or organ damage in the case of patients with autoimmune disorders. We report a new case of Kaposi's sarcoma induced by corticosteroids.

show abstract

Kaposi's sarcoma with visceral involvement after intraarticular and epidural injections of corticosteroids

Cited by 24 publications

References 32 publications

Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not"

Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not"

Kaposi’s Sarcoma after Long-Acting Steroids: Time until Remission and Drug Washout

Kaposi's sarcoma complicating long-term corticotherapy for rheumatoid arthritis

Contact Info

Product

Resources

About